Related Experiment Video
Updated: Feb 16, 2026
11:29
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
11.3K
MMP26: A potential biomarker for prostate cancer
Teng Cheng1, Fei Li1, Rui Wei1
1Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Summary
Matrix metalloproteinase-26 (MMP26) shows promise as a prostate cancer biomarker. Elevated serum MMP26 levels and tissue expression were observed in prostate cancer patients, suggesting its diagnostic potential.
Area of Science:
- Oncology
- Biochemistry
- Molecular Biology
Background:
- Prostate-specific antigen (PSA) is a widely used biomarker for prostate cancer (PCa).
- PSA screening faces criticism due to over-diagnosis and overtreatment of indolent PCa.
- Matrix metalloproteinases (MMPs), including MMP26, are implicated in various cancers.
Purpose of the Study:
- To investigate the potential of serum matrix metalloproteinase-26 (MMP26) as a diagnostic biomarker for prostate cancer (PCa).
- To evaluate MMP26 expression in prostate cancer tissues compared to benign prostatic hyperplasia (BPH) and control tissues.
Main Methods:
- Serum MMP26 levels were quantified using enzyme-linked immunosorbent assay (ELISA) in 160 participants (80 PCa, 40 BPH, 40 controls).
- MMP26 protein expression in tissues was assessed via immunohistochemistry.
Main Results:
- Serum MMP26 levels were significantly elevated in the PCa group compared to BPH and control groups.
- MMP26 protein expression was detected in PCa tissues but absent in BPH and control tissues.
Conclusions:
- MMP26 demonstrates potential as a novel serum biomarker for prostate cancer diagnosis.
- Further research is warranted to validate MMP26's clinical utility in PCa detection.
